powerpoint presentation program handouts/annapolis i… · transfusion 55.2 (2015): 235-244. kopko,...
TRANSCRIPT
![Page 1: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/1.jpg)
![Page 2: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/2.jpg)
![Page 3: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/3.jpg)
![Page 4: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/4.jpg)
![Page 5: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/5.jpg)
![Page 6: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/6.jpg)
• CCI less than 5,000-7,500 or PPR less than 20% at 1 hour • CCI requires platelet count of the infused product as well as
body surface area • Can use estimate of 3 x 1011 platelets for an apheresis
unit
![Page 7: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/7.jpg)
• Defining platelet refractoriness
• Integrating tiered laboratory data for patient management
• Describe the Hopkins Transfusion Coordinator Service (a.k.a. the PLT service)
• Current challenges
![Page 8: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/8.jpg)
Non-Immune causes Immune causes
Fever HLA antibodies
Infection/sepsis HPA antibodies
Disseminated intravascular coagulation ABO incompatibility
Sequestration (e.g., splenomegaly)
Medications
Bleeding
Veno-occlusive disease
Graft versus host disease
Non-immune causes much more common than immune causes
(non-immune factors present in 72-88% of cases and
HLA antibodies present in 25-39%)
![Page 9: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/9.jpg)
• Shortened platelet survival:
• No increment:
www.uptodate.com
![Page 10: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/10.jpg)
Jackman, RP., et al. "Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants." Blood 121.16 (2013): 3261-3266.
![Page 11: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/11.jpg)
![Page 12: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/12.jpg)
![Page 13: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/13.jpg)
• Pooled random donor
• UVB irradiated • Filtered
(leukoreduced) platelet concentrate (RDP)
• Filtered (leukoreduced) unmatched apheresis
TRAP Trial Study Group. "Leukocyte-reduction and UV-B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusion." N Eng J Med 337 (1997): 186.
![Page 14: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/14.jpg)
![Page 15: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/15.jpg)
![Page 16: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/16.jpg)
• Defining platelet refractoriness
• Causes & Epidemiology
• Integrating tiered laboratory data for patient management
• Describe the Hopkins Transfusion Coordinator Service (a.k.a. the PLT service)
• Current challenges
![Page 17: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/17.jpg)
Sensitivity for detecting anti-HLA antibodies: Flow cytometry > ELISA > cytotoxicity
![Page 18: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/18.jpg)
![Page 19: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/19.jpg)
![Page 20: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/20.jpg)
Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory patients." Transfusion 55.2 (2015): 235-244.
![Page 21: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/21.jpg)
Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory patients." Transfusion 55.2 (2015): 235-244.
![Page 22: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/22.jpg)
Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory patients." Transfusion 55.2 (2015): 235-244.
![Page 23: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/23.jpg)
Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory patients." Transfusion 55.2 (2015): 235-244.
![Page 24: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/24.jpg)
• HLA & HPA
• Used by some when HLA testing is in process
![Page 25: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/25.jpg)
![Page 26: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/26.jpg)
![Page 27: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/27.jpg)
Hod, Eldad, and Joseph Schwartz. "Platelet transfusion refractoriness." British journal of haematology 142.3 (2008): 348-360.
![Page 28: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/28.jpg)
Hod, Eldad, and Joseph Schwartz. "Platelet
transfusion refractoriness." British journal of
haematology 142.3 (2008): 348-360.
![Page 29: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/29.jpg)
• Defining platelet refractoriness
• Causes & Epidemiology
• Integrating tiered laboratory data for patient management
• Describe the Hopkins Transfusion Coordinator Service (a.k.a. the PLT service)
• Current challenges
![Page 30: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/30.jpg)
Fuller, AK., et al. "A comprehensive program to minimize platelet outdating." Transfusion 51.7 (2011): 1469-1476.
![Page 31: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/31.jpg)
Fuller, AK., et al. "A comprehensive program to minimize platelet outdating." Transfusion 51.7 (2011): 1469-1476.
![Page 32: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/32.jpg)
Fuller, AK., et al. "A comprehensive program to minimize platelet outdating." Transfusion 51.7 (2011): 1469-1476.
![Page 33: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/33.jpg)
• Defining platelet refractoriness
• Causes & Epidemiology
• Integrating tiered laboratory data for patient management
• Describe the Hopkins Transfusion Coordinator Service (a.k.a. the PLT service)
• Current challenges
![Page 34: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/34.jpg)
678-993-6251
![Page 35: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/35.jpg)
![Page 36: PowerPoint Presentation Program Handouts/Annapolis I… · Transfusion 55.2 (2015): 235-244. Kopko, PM., et al. "Methods for the selection of platelet products for alloimmune‐refractory](https://reader035.vdocuments.site/reader035/viewer/2022070100/601265865631af79564b05b5/html5/thumbnails/36.jpg)